CSTONE PHARMA-B(02616) first disclosed two new dual-antibody molecular targets for autoimmune/inflammatory diseases.

CSTONE PHARMA-B (02616) announced for the first time the two independently developed dual-specific antibody drug targets for autoimmune/inflammatory diseases: CS2013 (B-cell activating factor [BAFF]/proliferation-inducing ligand [APRIL]); and CS2015 (OX40 ligand [OX40L]/thymic stromal lymphopoietin [TSLP]). These two drugs have the best/same class innovation potential in the same class, both currently in the preclinical candidate compound (PCC) confirmation stage, with preclinical research data to be presented at relevant international academic conferences. In addition, CStone Pharma plans to initiate preparations for new drug clinical trial applications (IND) in the second half of 2025. CS2013 simultaneously targets two key ligands- BAFF and APRIL, required for the differentiation of B cells and plasma cells, through differentiated molecular design. Preclinical studies have shown that it can trigger highly efficient synergistic effects; at the same time, it has better pharmacokinetic properties compared to fusion protein drugs, such as a longer half-life and potential for longer dosing intervals, supporting subcutaneous administration. Planned indications include systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), IgA nephropathy (IgAN), and other B cell-related autoimmune diseases. As a potential same-class innovative drug, CS2015 simultaneously targets OX40L (a key ligand on immune response cells) and TSLP (an important warning molecule secreted by epithelial cells). It provides a new treatment strategy for type 2 inflammatory diseases such as atopic dermatitis (AD) and asthma by dual inhibition of key regulatory factors in Th2-mediated inflammatory responses. Preclinical data also show its potential for long half-life and subcutaneous administration. Dr. Frank Jiang, CEO, President of R&D, and Executive Director of CStone Pharma, stated: "There is a significant unmet need in the global field of autoimmune/inflammatory diseases - with a wide variety of diseases, a large patient population, and many requiring lifelong medication, it has become the second largest disease market after oncology. Compared to existing monoclonal antibody drugs, CStone Pharma's CS2013 is expected to achieve treatment optimization through synergistic blockade of mature targets, while CS2015 is expected to create a new mechanism of action. These two drugs together reflect our strategic expansion of the non-oncology pipeline, and are important practices in our vision of being a leader in improving global patient health through innovation."